Related Experiment Videos
Mutations in the gene encoding 21-hydroxylase detected by solid-phase minisequencing
1Department of Clinical Genetics, Juliane Marie Center, University Hospital, Rigshospitalet 4062, Copenhagen, Denmark.
Human Genetics
|January 1, 1997
Summary
A new assay screens for seven CYP21 gene mutations causing 21-hydroxylase deficiency. This reliable method aids in diagnosing patients and detecting carriers of the condition.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- Congenital adrenal hyperplasia (CAH) is often caused by mutations in the CYP21 gene, which encodes the enzyme 21-hydroxylase.
- Accurate and efficient screening for these mutations is crucial for diagnosis and carrier detection.
Purpose of the Study:
- To develop and validate a novel assay for detecting seven specific point mutations in the CYP21 gene.
- To provide a reliable tool for routine diagnosis of 21-hydroxylase deficiency and carrier screening.
Main Methods:
- Development of a solid-phase minisequencing assay utilizing 5'-biotinylated PCR products of the CYP21 gene.
- DNA is immobilized on streptavidin-coated microtiter wells for minisequencing after denaturation.
- Incorporation of a specific 3H-labelled deoxyribonucleotide to extend a detection primer, enabling mutation detection.
Main Results:
- The assay successfully screens for seven specific CYP21 mutations: Pro30Leu, I2-splice, Ile172Asn, Cluster-E6, Val281Leu, Gln318Stop, and Arg356Trp.
- The method clearly distinguishes between homozygous mutant, heterozygous, and normal individuals.
- The assay is fast, reliable, and suitable for screening multiple mutations within a single PCR amplicon.
Conclusions:
- The developed solid-phase minisequencing assay is a robust and efficient tool for CYP21 mutation screening.
- This assay facilitates routine diagnosis of 21-hydroxylase deficiency and carrier detection, improving patient management.